Calcium Dobesilate vs Flavonoids for the Treatment of Early Hemorrhoidal Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02782455
Recruitment Status : Recruiting
First Posted : May 25, 2016
Last Update Posted : January 27, 2017
Information provided by (Responsible Party):
Dr. SamiUllah, Services Hospital, Lahore

Brief Summary:
Haemorrhoids are vascular cushions in the anal canal that help in the control of stool. When inflamed they become pathological and may present with protrusion and bleeding. A randomized, triple blind , controlled study will be conducted to compare the efficacy of calcium dobesilate against flavanoids in the management of early haemorrhoidal disease.

Condition or disease Intervention/treatment Phase
Hemorrhoids Drug: Flavonoids Drug: CDobi Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Calcium Dobesilate vs Flavonoids for the Treatment of Early Hemorrhoidal Disease a Randomised Triple Blind Controlled Trial
Actual Study Start Date : December 2016
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium Hemorrhoids

Arm Intervention/treatment
Experimental: CDobi
Calcium dobesylate is given in this group
Drug: CDobi
Calcium dobesylate is administered
Other Name: dobesilate

Active Comparator: Flavono
Flavonoids are given in this group
Drug: Flavonoids
Daflon is administered
Other Name: Daflon

Primary Outcome Measures :
  1. Frequency of occurrence of rectal bleeding after usage of drug [ Time Frame: 1 weeks ]
    After the patients will be given the two drugs they will be followed for the frequency of occurrence of rectal bleeding till two weeks

Secondary Outcome Measures :
  1. regression of hemorrhoids [ Time Frame: 1 weeks ]
    Patients will under gone per rectal examination and proctoscopy to look for grades of hemorrhoids whether its has decreased or increased.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   13 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Grade I and Grade II hemorrhoids

Exclusion Criteria:

  • CLD
  • colorectal/ anorectal Malignancy
  • self medication
  • local Quack Hakeem medication
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02782455

Contact: Usman Ismat Butt, MBBS, FCPS +92-342-4343806
Contact: Sami Ullah, MBBS,BSc +92-344-4000322

Services Hospital Lahore Recruiting
Lahore, Punjab, Pakistan, 54000
Contact: Sami Ullah, MBBS    +92-344-4000322   
Sponsors and Collaborators
Services Hospital, Lahore
Study Director: Dr. Waris Farooka, MBBS, FCPS, FRCS, FACS Services Institute of Medical Sciences

Responsible Party: Dr. SamiUllah, Postgraduate trainee, Services Hospital, Lahore Identifier: NCT02782455     History of Changes
Other Study ID Numbers: DD
First Posted: May 25, 2016    Key Record Dates
Last Update Posted: January 27, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Vascular Diseases
Cardiovascular Diseases
Calcium, Dietary
Calcium Dobesilate
Bone Density Conservation Agents
Physiological Effects of Drugs